Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy
Status:
Completed
Trial end date:
2020-02-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate how well the standard treatment (platinum-based
doublet chemotherapy) in combination with denosumab works compared with the standard
treatment alone in patients with a type of lung cancer called "non small cell lung cancer"
(NSCLC) that has spread to other parts of the body.
Phase:
Phase 3
Details
Lead Sponsor:
European Thoracic Oncology Platform
Collaborators:
Amgen European Organisation for Research and Treatment of Cancer - EORTC